Compare DexCom, Inc. (DXCM) vs Nutrien Ltd (NTR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Nutrien Ltd — how do they compare? DexCom, Inc. trades at $77.03 (market cap $28.06B), while Nutrien Ltd trades at $66.75 (market cap $32.46B). The key difference: Nutrien Ltd is the larger of the two by market cap, and Nutrien Ltd pays a 3.22% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | NTR | |
|---|---|---|
Market Cap | $28.06B | $32.46B |
Sector | Health | Basic Materials |
52-Week High | $89.53 | $83.94 |
52-Week Low | $54.84 | $53.64 |
Enterprise Value | $27.03B | $45.62B |
Dividend Yield | — | 3.22% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $77.31, up 4.3% on the day, with a bullish technical outlook as it approaches resistance near $78. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.56 surpassing expectations of $0.47. Revenue growth accelerated to $4.66 billion in 2025, while net income margin expanded to 17.93%. Recent regulatory approvals, including Health Canada authorization for the G7 15-day CGM, support continued international expansion.
The stock offers growth potential with analyst consensus price target of $84.33, though high valuation multiples (P/E 31.21) and competition in the CGM market present risks. Expansion into non-insulin Type 2 diabetes and pediatric markets could drive future revenue, but commercial uptake remains unproven. Institutional sentiment remains strongly bullish with 80% buy ratings.
Nutrien (NTR) trades at $67.04, down 2.33% on the day, with a bullish technical signal from moving averages but bearish oscillators. The company shows improving fundamentals with Q1 2026 EPS beating expectations and a net income margin of 8.58%. Recent news highlights strong fertilizer demand and cost-cutting efforts, though input cost pressures persist. Cash flow trends indicate consistent operational strength despite negative net cash flow in recent periods.
Outlook remains positive with analyst consensus pointing to a $77.67 price target and 63.64% buy ratings. Key opportunities include robust potash sales and healthy industry demand, while risks involve volatile input costs and margin compression from supply chain challenges. The stock presents a value proposition with a P/E of 13.92 trading below analyst targets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Nutrien Ltd
Created in 2018 as a result of the merger between PotashCorp and Agrium, Nutrien is the world's largest fertilizer producer by capacity. Nutrien produces the three main crop nutrients--nitrogen, potash, and phosphate--although its main focus is potash, where it is the global leader in installed capacity with roughly 20% share. The company is also the largest agricultural retailer in the United States, selling fertilizers, crop chemicals, seeds, and services directly to farm customers through its brick-and-mortar stores and online platforms.
Read more on NTR →
